https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-03 / J Immunol Res 2014;2014:796856
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-03 / J Immunol Res 2014;2014:7968562014-04-03 00:00:002019-02-15 08:46:25Current vaccine trials in glioblastoma: a review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-03 / PLoS ONE 2014;9(4):e93886
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-03 / PLoS ONE 2014;9(4):e938862014-04-03 00:00:002019-02-15 08:46:18Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-01 / Clin. Cancer Res. 2014 Mar;20(5):1095-103
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-01 / Clin. Cancer Res. 2014 Mar;20(5):1095-1032014-03-01 00:00:002019-02-15 08:39:45Natural killer cells: the secret weapon in dendritic cell vaccination strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-01 / Discov Med 2014 Mar;17(93):145-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-01 / Discov Med 2014 Mar;17(93):145-542014-03-01 00:00:002019-02-15 08:46:25Novel approaches and mechanisms of immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-28 / Clin. Cancer Res. 2014 May;20(9):2433-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-28 / Clin. Cancer Res. 2014 May;20(9):2433-442014-02-28 00:00:002019-02-15 08:39:40Phase I dendritic cell p53 peptide vaccine for head and neck cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-27 / Oncoimmunology 2014 Jan;3(1):e27589
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-27 / Oncoimmunology 2014 Jan;3(1):e275892014-02-27 00:00:002019-02-15 08:48:45Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-18 / J Immunother Cancer 2014;2:4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-18 / J Immunother Cancer 2014;2:42014-02-18 00:00:002019-02-15 08:46:24Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-05 / Cancer Immunol Res 2014 May;2(5):404-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-05 / Cancer Immunol Res 2014 May;2(5):404-92014-02-05 00:00:002019-02-15 08:48:45Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-13 / Hum Vaccin Immunother 2014;10(4):970-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-13 / Hum Vaccin Immunother 2014;10(4):970-62014-01-13 00:00:002014-01-13 00:00:00Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-03 / Cancer Immunol. Immunother. 2014 Apr;63(4):321-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-03 / Cancer Immunol. Immunother. 2014 Apr;63(4):321-332014-01-03 00:00:002019-02-15 08:39:42Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
